Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Executive Summary
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
You may also be interested in...
Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation
By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.
Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022
The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.
Jazz Pharma Zeros In On Essential Tremor With Cavion Buy
Jazz’s $312.5m acquisition will add to the company’s pipeline of products in neurological conditions, but only at the Phase-II stage.
Need a specific report? 1000+ reports available
Buy Reports